ArticleMolecular therapy. Nucleic acids2026
Aging alters synergistic microRNA networks in exosomes to stimulate repair in lung injury and skin wound healing.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) deliver their effects via paracrine signaling, including the release of extracellular vesicles (EVs), which transfer microRNAs (miRNAs) and mRNAs to recipient cells. Aging alters exosome composition and function, raising questions about donor age, the use of autologous vs. allogeneic donors, and exosome dose and dosing frequency for exosome-based therapies in fibrotic lung disease. To address these gaps, we investigated how exosomes from younger (28-39 years, adult-exo) and older (58-66 years) donors influence fibrosis and tissue repair. Exosomes were delivered intravenously to 18-months-old male C57BL/6 mice on day 12 post-bleomycin (BLM), with lung injury evaluated on day 21 by histologic, molecular, mitochondrial, and telomere analyses. A human skin injury model was used to quantitate exosome-mediated wound healing. Adult-exo reduced lung injury and accelerated skin wound closure. RNA sequencing (RNA-seq) revealed that adult-exo carried elevated antifibrotic miRNAs, such as let-7. Pathway enrichment linked this cargo to extracellular matrix (ECM) remodeling, mitochondrial function, and senescence. Adult-exo treatment also downregulated fibrosis- and senescence-associated miRNAs, such as miR-34, in lung tissue.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.